TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Tag Archives: James Black
Guest Blogspot: Pharmaceutical R & D – the value of radical innovation versus incremental progress
What we really want is affordable products that benefit patients, whether or not they are “innovative” in the usual sense of the word. Scientific innovation is not a medical end in itself. The ultimate aim of pharmaceutical R&D is to … Continue reading
Posted in Business, competition, Department of Health, Drugs, Emerging technologies, Finance, Healthcare, Innovation, NHS, Patients, Pharma, Policy, Research, Technology, Uncategorized
Tagged 2020health, Alderlin, angina, atenolol, beta-blocker, cimetidine, competition, David Jack, definition of innovation, Department of Health, Drugs, Eraldin, government, heart drug, incremental, Inderal, innovation, innovative, James Black, medicine, Michael Rawlins, National Health Service, NHS, NICE, patient, Patients, pharmaceutical, practolol, pricing, pronethalol, propranolol, R&D, ranitidine, Research, Sir David Jack, Sir James Black, Sir Michael Rawlins, Tagamet, Tenormin, ulcer drug, value-based, value-based pricing, Zantac
Leave a comment
2020health's Blog 